帕博利珠单抗联合仑伐替尼一线治疗晚期非透明细胞肾细胞癌:KEYNOTE-B61 Ⅱ期试验更新结果
KEYNOTE-B61 是一项单臂、多中心、Ⅱ期试验,评估帕博利珠单抗联合仑伐替尼一线治疗晚期非透明细胞肾细胞癌。158 例患者接受治疗,中位随访 22.8 个月,客观缓解率 51%(95%CI 43-59),中位缓解持续时间 19.5 个月,未出现新的安全信号。结果支持该方案作为晚期非透明细胞肾细胞癌的一线治疗选择。
要点
- 帕博利珠单抗联合仑伐替尼一线治疗晚期 nccRCC 的 ORR 为 51%(95%CI 43-59)。
- 13 例(8.2%)达确认完全缓解,67 例(42%)达确认部分缓解。
- 3-4 级治疗相关不良事件发生率为 58%,无治疗相关死亡。
核心结论
- 经过约 2 年随访,帕博利珠单抗联合仑伐替尼在 KEYNOTE-B61 中显示出持久的抗肿瘤活性,且无新的安全信号。
- 结果支持帕博利珠单抗联合仑伐替尼作为晚期 nccRCC 的一线治疗选择。
研究设计与样本
- 单臂、多中心、Ⅱ期 KEYNOTE-B61 试验。
- 纳入既往未治疗的晚期 nccRCC 患者,年龄≥18 岁。
- 共 158 例患者接受至少一剂研究治疗。
- 所有患者接受帕博利珠单抗 400 mg 静脉注射每 6 周一次(最多 18 周期,约 2 年)联合仑伐替尼 20 mg 口服每日一次。
- 主要终点为盲法独立中心评审依据 RECIST v1.1 评估的客观缓解率(ORR)。
主要发现
- 中位随访 22.8 个月(范围 16.6-27.6)。
- ORR 为 51%(95%CI 43-59)。
- 13 例(8.2%)达确认完全缓解,67 例(42%)达确认部分缓解。
- 在确认缓解的亚组中,中位缓解持续时间(DOR)为 19.5 个月(范围 1.5+ 至 23.5+)。
- ORR 在各亚组中总体一致,包括组织学亚型(34-67%)和肉瘤样特征存在(47%)。
临床怎么用
- 对于既往未治疗的晚期 nccRCC 患者,可考虑帕博利珠单抗联合仑伐替尼作为一线治疗选择。
- 治疗期间需关注 3-4 级治疗相关不良事件(发生率 58%),但无治疗相关死亡。
局限性
- 单臂设计,无对照臂。
- 随访时间仍有限(中位 22.8 个月)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Initial results from the KEYNOTE-B61 trial demonstrated that pembrolizumab combined with lenvatinib has promising antitumor activity in previously untreated advanced non-clear-cell renal cell carcinoma (nccRCC). We report updated efficacy and safety results after nearly 2 yr of follow-up. METHODS: The single-arm, multicenter, phase 2 KEYNOTE-B61 trial enrolled patients aged ≥18 yr with previously untreated advanced nccRCC. All participants received pembrolizumab 400 mg intravenously every 6 wk (up to 18 cycles, approx. 2 yr) plus lenvatinib 20 mg orally once daily. The primary endpoint was the objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumors v1.1 as assessed on blinded independent central review. Duration of response (DOR) and safety were secondary endpoints. KEY FINDINGS AND LIMITATIONS: A total of 158 patients received at least one dose of study treatment. Median follow-up was 22.8 mo (range 16.6-27.6). The ORR was 51% (95% confidence interval 43-59); 13 patients (8.2%) had a confirmed complete response and 67 (42%) had a confirmed partial response. In the subgroup with a confirmed response, median DOR was 19.5 mo (range 1.5+ to 23.5+). ORR was generally consistent across subgroups, including histologic subtypes (34-67%) and the presence of sarcomatoid features (47%). Grade 3 or 4 treatment-related adverse events were reported for 92 patients (58%). No deaths due to treatment-related adverse events occurred. CONCLUSION AND CLINICAL IMPLICATIONS: After approximately 2 yr of follow-up, pembrolizumab plus lenvatinib showed durable antitumor activity in KEYNOTE-B61, with no new safety signals. These results support pembrolizumab + lenvatinib as a first-line treatment option for advanced nccRCC.
引用
- Voss MH, Gurney H, Atduev V, et al. First-line Pembrolizumab Plus Lenvatinib for Advanced Non-clear-cell Renal Cell Carcinoma: Updated Results from the Phase 2 KEYNOTE-B61 Trial. Eur Urol. 2025. PMID: 40707309. doi:10.1016/j.eururo.2025.05.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。